^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Marginal Zone Lymphoma |
| Drug: | Breyanzi (lisocabtagene maraleucel) (CD19-targeted CAR-T immunotherapy) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Marginal Zone Lymphoma: Suggested treatment regimens…Anti-CD19 CAR T-cell therapy (only after ≥2 prior chemoimmunotherapy regimens…Lisocabtagene maraleucel
